IRIS Accounts Production v25.4.0.155 02887403 Board of Directors 1.1.25 31.12.25 31.12.25 false true false false false true false iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 02887403 2024-12-31 02887403 2025-12-31 02887403 2025-01-01 2025-12-31 02887403 2023-12-31 02887403 2024-01-01 2024-12-31 02887403 2024-12-31 02887403 ns15:EnglandWales 2025-01-01 2025-12-31 02887403 ns14:PoundSterling 2025-01-01 2025-12-31 02887403 ns10:Director1 2025-01-01 2025-12-31 02887403 ns10:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 02887403 ns10:SmallEntities 2025-01-01 2025-12-31 02887403 ns10:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 02887403 ns10:SmallCompaniesRegimeForDirectorsReport 2025-01-01 2025-12-31 02887403 ns10:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 02887403 ns10:FullAccounts 2025-01-01 2025-12-31 02887403 1 2025-01-01 2025-12-31 02887403 ns10:Director2 2025-01-01 2025-12-31 02887403 ns10:RegisteredOffice 2025-01-01 2025-12-31 02887403 ns5:CurrentFinancialInstruments 2025-12-31 02887403 ns5:CurrentFinancialInstruments 2024-12-31 02887403 ns5:ShareCapital 2025-12-31 02887403 ns5:ShareCapital 2024-12-31 02887403 ns5:RetainedEarningsAccumulatedLosses 2025-12-31 02887403 ns5:RetainedEarningsAccumulatedLosses 2024-12-31 02887403 ns5:IntangibleAssetsOtherThanGoodwill 2025-01-01 2025-12-31 02887403 ns5:ShortLeaseholdAssets ns5:LandBuildings 2025-01-01 2025-12-31 02887403 ns5:PlantMachinery 2025-01-01 2025-12-31 02887403 ns5:FurnitureFittings 2025-01-01 2025-12-31 02887403 ns5:PatentsTrademarksLicencesConcessionsSimilar 2024-12-31 02887403 ns5:PatentsTrademarksLicencesConcessionsSimilar 2025-01-01 2025-12-31 02887403 ns5:PatentsTrademarksLicencesConcessionsSimilar 2025-12-31 02887403 ns5:PatentsTrademarksLicencesConcessionsSimilar 2024-12-31 02887403 ns5:ShortLeaseholdAssets ns5:LandBuildings 2024-12-31 02887403 ns5:PlantMachinery 2024-12-31 02887403 ns5:FurnitureFittings 2024-12-31 02887403 ns5:ShortLeaseholdAssets ns5:LandBuildings 2025-12-31 02887403 ns5:PlantMachinery 2025-12-31 02887403 ns5:FurnitureFittings 2025-12-31 02887403 ns5:ShortLeaseholdAssets ns5:LandBuildings 2024-12-31 02887403 ns5:PlantMachinery 2024-12-31 02887403 ns5:FurnitureFittings 2024-12-31 02887403 ns5:CostValuation 2024-12-31 02887403 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-12-31 02887403 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-12-31 02887403 ns5:AcceleratedTaxDepreciationDeferredTax 2025-12-31 02887403 ns5:AcceleratedTaxDepreciationDeferredTax 2024-12-31 02887403 ns5:DeferredTaxation 2024-12-31 02887403 ns5:DeferredTaxation 2025-01-01 2025-12-31 02887403 ns5:DeferredTaxation 2025-12-31

REGISTERED NUMBER: 02887403 (England and Wales)

Unaudited Financial Statements for the Year Ended 31 December 2025

for

Indoor Biotechnologies Limited

| Indoor Biotechnologies Limited (Registered number: 02887403) |

Contents of the Financial Statements

for the Year Ended 31 December 2025

Page |

| Company Information | 1 |

| Statement of Financial Position | 2 |

| Notes to the Financial Statements | 4 |

| Indoor Biotechnologies Limited |

Company Information

for the Year Ended 31 December 2025

| Directors: | Dr M D Chapman

| M C Watkins

| Registered office: | 114-120 Northgate Street

| Chester

| CH1 2HT

| Registered number: | 02887403 (England and Wales)

| Accountants: | Ellis & Co

| Chartered Accountants

| 114-120 Northgate Street

| Chester

| CH1 2HT

| Indoor Biotechnologies Limited (Registered number: 02887403) |

Statement of Financial Position

31 December 2025

| 31/12/25 | 31/12/24 |

| Notes | £ | £ | £ | £ |

Fixed assets

Intangible assets | 4 | 12,937 |  | 18,293 |  |

Tangible assets | 5 | 153,853 |  | 183,892 |  |

Investments | 6 | 1 |  | 1 |  |

166,791 |  | 202,186 |  |

Current assets

Stocks | 525,955 |  | 534,784 |  |

Debtors | 7 | 506,210 |  | 529,827 |  |

Cash at bank and in hand | 1,140,561 |  | 1,058,733 |  |

2,172,726 |  | 2,123,344 |  |

Creditors

Amounts falling due within one year | 8 | 284,107 |  | 370,525 |  |

Net current assets | 1,888,619 |  | 1,752,819 |  |

Total assets less current liabilities | 2,055,410 |  | 1,955,005 |  |

Provisions for liabilities | 9 | 19,392 |  | 21,072 |  |

Net assets | 2,036,018 |  | 1,933,933 |  |

Capital and reserves

Called up share capital | 2 |  | 2 |  |

Retained earnings | 2,036,016 |  | 1,933,931 |  |

Shareholders' funds | 2,036,018 |  | 1,933,933 |  |

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2025.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2025 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:

(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and

(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

| Indoor Biotechnologies Limited (Registered number: 02887403) |

Statement of Financial Position - continued

31 December 2025

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 18 March 2026 and were signed on its behalf by:

Dr M D Chapman - Director

| Indoor Biotechnologies Limited (Registered number: 02887403) |

Notes to the Financial Statements

for the Year Ended 31 December 2025

1. | Statutory information

| Indoor Biotechnologies Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. | Accounting policies

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Turnover

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer, usually on despatch of the goods; the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

| Revenue from the rendering of services is measured by reference to the stage of completion of the service transaction at the end of the reporting period provided that the outcome can be reliably estimated. When the outcome cannot be reliably estimated, revenue is recognised only to the extent that expenses recognised are recoverable.

| Intangible assets

| Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

| Patents and licences - straight line over between 8 and 10 years

| If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.

| Leasehold improvements | - | 10% on cost

| Laboratory equipment | - | straight line over 7 years

| Fixtures, fittings and equipment | - | 25% on cost

| Investments in subsidiaries

| Investments in subsidiary undertakings are recognised at cost.

| Stocks

| Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

| Indoor Biotechnologies Limited (Registered number: 02887403) |

Notes to the Financial Statements - continued

for the Year Ended 31 December 2025

2. | Accounting policies - continued

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Foreign currencies

| Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the reporting date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

| Leasing commitments

| Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease.

| Pension costs and other post-retirement benefits

| The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

| Government grants

| Government grants are recognised at the fair value of the asset received or receivable. Grants are not recognised until there is reasonable assurance that the company will comply with the conditions attaching to them and the grants will be received.

| Government grants are recognised using the accrual model. Under the accrual model, government grants relating to revenue are recognised on a systematic basis over the periods in which the company recognises the related costs for which the grant is intended to compensate. Grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the entity with no future related costs are recognised in income in the period in which it becomes receivable.

| Grants relating to assets are recognised in income on a systematic basis over the expected useful life of the asset. Where part of a grant relating to an asset is deferred, it is recognised as deferred income and not deducted from the carrying amount of the asset.

| Indoor Biotechnologies Limited (Registered number: 02887403) |

Notes to the Financial Statements - continued

for the Year Ended 31 December 2025

3. | Employees and directors

| The average number of employees during the year was 10 (2024 - 9 ) .

4. | Intangible fixed assets

| Patents

| and

| licences

£ |

| Cost

| At 1 January 2025

| and 31 December 2025 | 60,719 |  |

| Amortisation

| At 1 January 2025 | 42,426 |  |

| Amortisation for year | 5,356 |  |

| At 31 December 2025 | 47,782 |  |

| Net book value

| At 31 December 2025 | 12,937 |  |

| At 31 December 2024 | 18,293 |  |

5. | Tangible fixed assets

| Fixtures, |

| fittings |

| Leasehold |  | Laboratory |  | and |

| improvements |  | equipment |  | equipment |  | Totals

£ | £ | £ | £ |

| Cost

| At 1 January 2025 | 460,018 |  | 323,733 |  | 146,720 |  | 930,471 |  |

| Additions | 18,286 |  | 22,556 |  | 6,937 |  | 47,779 |  |

| Disposals | - |  | - |  | (164 | ) | (164 | ) |

| At 31 December 2025 | 478,304 |  | 346,289 |  | 153,493 |  | 978,086 |  |

| Depreciation

| At 1 January 2025 | 337,958 |  | 267,233 |  | 141,388 |  | 746,579 |  |

| Charge for year | 47,830 |  | 25,518 |  | 4,470 |  | 77,818 |  |

| Eliminated on disposal | - |  | - |  | (164 | ) | (164 | ) |

| At 31 December 2025 | 385,788 |  | 292,751 |  | 145,694 |  | 824,233 |  |

| Net book value

| At 31 December 2025 | 92,516 |  | 53,538 |  | 7,799 |  | 153,853 |  |

| At 31 December 2024 | 122,060 |  | 56,500 |  | 5,332 |  | 183,892 |  |

| Indoor Biotechnologies Limited (Registered number: 02887403) |

Notes to the Financial Statements - continued

for the Year Ended 31 December 2025

6. | Fixed asset investments

| Shares in

| group

| undertakings

£ |

| Cost

| At 1 January 2025

| and 31 December 2025 | 1 |  |

| Net book value

| At 31 December 2025 | 1 |  |

| At 31 December 2024 | 1 |  |

7. | Debtors: amounts falling due within one year |

| 31/12/25 |  | 31/12/24

£ | £ |

| Trade debtors | 366,952 |  | 424,607 |  |

| Other debtors | 139,258 |  | 105,220 |  |

506,210 |  | 529,827 |  |

8. | Creditors: amounts falling due within one year |

| 31/12/25 |  | 31/12/24

£ | £ |

| Trade creditors | 164,502 |  | 243,414 |  |

| Taxation and social security | 91,111 |  | 100,718 |  |

| Other creditors | 28,494 |  | 26,393 |  |

284,107 |  | 370,525 |  |

9. | Provisions for liabilities

| 31/12/25 |  | 31/12/24

£ | £ |

| Deferred tax

| Accelerated capital allowances | 19,392 |  | 21,072 |  |

| Deferred |

| tax |

£ |

| Balance at 1 January 2025 | 21,072 |  |

| Credit to Statement of Income and Retained Earnings during year | (1,680 | ) |

| Balance at 31 December 2025 | 19,392 |  |

| Indoor Biotechnologies Limited (Registered number: 02887403) |

Notes to the Financial Statements - continued

for the Year Ended 31 December 2025

10. | Other financial commitments

| At 31 December 2025, the company had total commitments under non-cancellable operating leases over the remaining life of those leases of £219,612 (2024 - £334,298). The amount payable within one year in respect of these leases was £109,571 (2024 - £114,686).